Crinetics Pharmaceuticals Announces Stock Option Grants
SAN DIEGO, December 10, 2025 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) is shaping its workforce dynamics by announcing the granting of non-qualified stock options and restricted stock units (RSUs) to new employees. A total of 39,575 shares were awarded, along with 26,525 RSUs, under the company’s 2021 Employment Inducement Incentive Award Plan.
Understanding the 2021 Inducement Plan
The 2021 Inducement Plan serves as a strategic tool for Crinetics, exclusively designed to attract talent who have not previously worked with the company. This plan allows for equity awards tailored for individuals starting employment after a substantial break, adhering to Nasdaq Listing Rule 5635(c)(4). The stock options provided have an exercise price set at $48.06, matching the closing price of Crinetics’ common stock on this notable date.
The stock options are structured to vest over four years, with a quarter of the shares becoming available after the first year and the remaining shares vesting monthly. Similarly, RSUs are slated to vest in equal annual increments starting a year after employment begins, fostering long-term commitment among the new hires. The vesting schedules for both types of awards are contingent upon continued employment at Crinetics.
Crinetics’ Commitment to Employee Growth
This initiative underscores Crinetics Pharmaceuticals’ commitment not just to its mission of developing treatments for endocrine diseases, but also to nurturing its team. By offering stock options, the company promotes a culture of ownership, empowering employees to contribute actively to the company’s success. This approach aligns personal achievements with corporate objectives, creating a motivated workforce poised for innovation.
The Vision of Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is dedicated to revolutionizing the landscape of endocrine disease therapy. Focusing on the development of innovative therapies, the company targets G-protein coupled receptors (GPCRs) with specialized small molecules, intent on addressing critical patient needs.
The hallmark product of Crinetics, PALSONIFY™ (paltusotine), is groundbreaking as the first oral treatment approved for patients with acromegaly who have not benefitted sufficiently from surgery. Beyond acromegaly, Crinetics is exploring paltusotine's efficacy in treating carcinoid syndrome linked to neuroendocrine tumors.
Diverse Development Pipeline
Crinetics boasts a comprehensive pipeline with over ten programs in various stages of investigation. Among these, atumelnant is notably advancing through late-stage clinical trials focusing on congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Additionally, Crinetics is undertaking research on diverse endocrine disorders, including neuroendocrine tumors, Graves’ disease, polycystic kidney disease, and diabetes, showcasing a robust commitment to addressing multiple health challenges.
Engaging with Investors and the Media
For inquiries regarding investor relations, Gayathri Diwakar serves as the dedicated Head of Investor Relations at Crinetics Pharmaceuticals. She is reachable at gdiwakar@crinetics.com or by phone at (858) 345-6340.
In terms of media relations, Natalie Badillo heads Corporate Communications. She can be contacted at nbadillo@crinetics.com or by calling (858) 450-6464. This open line of communication not only demonstrates transparency but also reflects the company’s mission to engage meaningfully with all stakeholders.
Frequently Asked Questions
What is the purpose of the stock options granted by Crinetics?
The stock options aim to attract new employees and incentivize their contributions to the company's growth.
How does the 2021 Inducement Plan work?
This plan allows Crinetics to provide equity awards to non-employees or those returning after a break, enhancing recruitment efforts.
What are the key products developed by Crinetics Pharmaceuticals?
PALSONIFY™ is Crinetics' leading product, providing treatment for acromegaly, with further developments targeting various endocrine disorders.
How long do the stock options take to vest?
The stock options vest over four years, beginning with a quarter of the shares available after the first year.
Who can be contacted for investor inquiries at Crinetics?
Gayathri Diwakar oversees investor relations and is available for any related questions or discussions.
